Get started
iTeos Therapeutics, Inc.iTeos Therapeutics, Inc.iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Options

ITOS fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
ITOS has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company